Nintedanib

Nintedanib
Properties
Appearance	Light yellow to yellow solid
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Nintedanib
	Nintedanib
Clinical data
Trade names	Vargatef, Ofev
Other names	BIBF 1120
AHFS/Drugs.com	Monograph
MedlinePlus	a615009
License data	US DailyMed: Nintedanib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EX09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	4.7%
Protein binding	97.8%
Metabolism	Esterases, glucuronidation
Elimination half-life	10–15 hrs
Excretion	93% via faeces
Identifiers
	IUPAC name Methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate;
CAS Number	656247-17-5 ; as esylate: 656247-18-6;
PubChem CID	9809715; as esylate: 135476717;
IUPHAR/BPS	5936;
DrugBank	DB09079 ; as esylate: DBSALT001111;
ChemSpider	7985471 ; as esylate: 7985470;
UNII	G6HRD2P839; as esylate: 42F62RTZ4G;
KEGG	D10481; as esylate: D10396;
ChEBI	CHEBI:85164 ; as esylate: CHEBI:85170;
ChEMBL	ChEMBL502835; as esylate: ChEMBL3039504;
PDB ligand	XIN (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID201025948 ;
ECHA InfoCard	100.237.441
Chemical and physical data
Formula	C31H33N5O4
Molar mass	539.636 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1;
	InChI InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-; Key:XZXHXSATPCNXJR-ZIADKAODSA-N;
	(what is this?) (verify)

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration (FDA).

Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.

Ofev was developed by Boehringer Ingelheim. It received U.S. Food and Drug Administration (FDA) approval for use for idiopathic pulmonary fibrosis in 2014 – one of only two drugs available for treating IPF – and numerous studies since have demonstrated its effectiveness in slowing the progressive, terminal lung disease.